Form 4: CARGO Therapeutics Director Krishnan Viswanadhan Granted 25,000 Stock Options

CARGO Therapeutics, Inc. Director Krishnan Viswanadhan was granted 25,000 stock options with an exercise price of $4.35, vesting over one year or by the next Annual Meeting.

Summary

• Krishnan Viswanadhan, a Director of CARGO Therapeutics, Inc. (CRGX), was granted 25,000 stock options.
• The options have an exercise price of $4.35 per share.
• The transaction date for this grant was June 18, 2025.
• The options are scheduled to expire on June 17, 2035.
• 100% of the shares subject to the option will vest on the earlier of the one-year anniversary of June 18, 2025, or the next Annual Meeting following June 18, 2025, contingent on Mr. Viswanadhan's continued service to the Issuer.
• Following this transaction, Mr. Viswanadhan beneficially owns 25,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates alignment of a director's interests with shareholders through equity compensation, which is a standard and generally well-regarded practice.

Positives

• The grant of stock options to a director aligns the director's interests with those of the shareholders, as the options gain value if the company's stock price increases.
• It represents a form of long-term incentive for the director's continued service and contribution to the company's success.

Future Outlook

This filing pertains to an insider compensation event and does not provide a general future outlook for the company's operations or financial performance.

Industry Context

The granting of stock options to directors is a common practice across various industries, including biotechnology and pharmaceuticals, to incentivize leadership and align their financial interests with company performance and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard component of executive and director compensation packages in publicly traded companies, particularly in growth-oriented sectors like biotechnology.
• The vesting schedule, tied to continued service and a one-year anniversary or next annual meeting, is typical for such grants, aiming to retain talent and encourage long-term commitment.

Management Changes

Related Party Transactions

• The grant of stock options to Krishnan Viswanadhan, a Director of CARGO Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options could lead to minor dilution if exercised, but it also aligns the director's financial incentives with shareholder value creation.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest on the earlier of June 18, 2026 (one-year anniversary of grant) or the next Annual Meeting following June 18, 2025, subject to continued service.
• Upon vesting, the director will have the right to exercise the options at $4.35 per share until the expiration date of June 17, 2035.

Key Dates

Keywords

CARGO Therapeutics, CRGX, Stock Option Grant, Insider Transaction, Director Compensation, SEC Form 4, Equity Compensation, Vesting Schedule